News

ABL is pleased to announce the allowance of a new patent covering new Hepatitis B primers and kits hybridizing to DNA or mRNA of the Hepatitis B Virus Polymerase gene.

We are pleased to announce that the DeepChek®-HIV RT/PROT assay and the DeepChek®-HIV INT assay successfully passed a national and independent quality control program in France and Switzerland and obtained 100% positive results on sensibility, 100% on specificity and also 100% on scoring on HIV geno…

Together with our partner in Italy, Technogenetics, we are delighted to have two international experts in the field of molecular virology share their experience in clinical microbiology and laboratory management using our solutions (reagents and software) at the Technogenetics Satellite Symposium or…

Advanced Biological Laboratories (ABL) S.A. and ABALAT S.A. are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Mexico. See current channel partners.

We are pleased to share with you recent updates on ABL Diagnostics solutions: DeepChek Software v3.27 released including: Largescale mode: launch analyses on multiple samples simultaneously New One-page Report New version of HIVDB drug resistance guidelines (v8.4) HCV reference subtypes updated acco…

Advanced Biological Laboratories (ABL) S.A. and SafeBlood BioAnalytica S.A. are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Greece. See current channel partners.

ABL is pleased to announce the immediate available of two new DeepChek® Assays intended to be used for: Determining eligibility for CCR5 antagonist treatment in patients infected with human immunodeficiency virus 1 (HIV-1) – DeepChek®-HIV V3 Loop/Tropism Assay HBV genotyping, drug resistance a…

Advanced Biological Laboratories S.A. and Right to Care enter into an exclusive distribution and development collaboration (open source) agreement covering EQUIP in 17 developing countries to strengthen HIV (and other infectious disease) treatment and prevention. Johannesburg (South Africa), Boston…

South Africa/Luxembourg, Tuesday, 4 July 2017: The Foundation for Professional Development (FPD) Group and Right to Care Group, joined forces to bring their healthcare technology under one umbrella for the advancement of health outcomes in developing countries. The new organisation which will house…

Advanced Biological Laboratories (ABL) S.A. and Kron Científica e Industrial S.A. are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Guatemala. See current channel partners.

Fédialis Médica a le plaisir de vous informer que les hôpitaux de la Pitié-Salpêtrière à Paris, ainsi que le ​CHU de ​Fort de France en Martinique utilisent notre logiciel CeGInaDis (version CeGIDD du logiciel NADIS) pour leurs activités de routine CeGIDD.

Advanced Biological Laboratories (ABL) S.A. and BADER SULTAN & BROTHERS CO W.L.L are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Kuwait. See current channel partners.

I’m interested!

Fédialis Médica a le plaisir de vous informer de la signature d’un partenariat avec l’AFRAVIH (www.afravih.org/) dans le but de tester l’utilisation du dossier médical informatisé NADIS pour le suivi et la prise en charge de patients vivant avec une pathologie chronique (VIH, hépatite, t…

ABL is pleased to announce the official release of its SeqHepB v6 interpretation system & database. Dedicated to the management of Viral Hepatitis B (HBV) sequencing data, the software can handle Capillary Electrophoresis or Next Generation Sequencing data, performs genotyping and mutation detec…